Rewiring the Tumor Engine: How Metabolism Could Become Cancer’s Next Weak Spot

Cancer cells do not simply grow faster than healthy cells; they run their entire metabolic machinery differently. This phenomenon, known as metabolic reprogramming, allows tumors to sustain rapid proliferation, survive in nutrient-poor environments, evade immune surveillance and resist chemotherapy. Now, a collection of studies published in Frontiers in Drug Discovery suggests that this metabolic rewiring could become cancer’s most exploitable vulnerability, offering new drug targets that go far beyond traditional approaches.

One of the most striking findings comes from Shrestha and colleagues, who investigated two microRNAs, miR-143-3p and miR-506-3p, in non-small cell lung cancer. By combining laboratory cell models with animal studies, they demonstrated that increasing the levels of these two microRNAs significantly reduced cancer cell proliferation and migration while also inhibiting tumor growth in mice. The result points toward a combinatorial microRNA therapy for lung cancer, one of the most common and difficult-to-treat malignancies worldwide.

MicroRNAs are small RNA molecules that regulate gene expression after transcription, essentially acting as molecular brakes on protein production. Because a single microRNA can control dozens of downstream targets simultaneously, they offer a broad-spectrum approach to shutting down multiple cancer-promoting pathways at once. This is particularly relevant in metabolic reprogramming, where cancer cells rely on interconnected networks rather than a single mutated gene.

Building on this concept, Van den Bosch and colleagues developed a synthetic mimic of the tumor-suppressive microRNA miR-7-5p, named 5A2. When formulated in a lipid nanoparticle and delivered as INT-5A2, the treatment produced significant reductions of liver tumors in an experimental mouse model bearing human liver tumors. Remarkably, the researchers found that 5A2 reduced key metabolic enzymes driving glycolysis and glutaminolysis, leading to decreased lactic acid secretion, reduced glycolytic flux and lower intracellular glutamate levels. This suggests that a single microRNA can effectively dismantle the metabolic engine that fuels tumor growth.

Glycolysis and glutaminolysis are two hallmark metabolic pathways exploited by cancer cells. Glycolysis allows tumors to break down glucose even in the presence of oxygen, a phenomenon first described by Otto Warburg nearly a century ago. Glutaminolysis, meanwhile, provides nitrogen and carbon skeletons that support rapid cell division. By simultaneously suppressing both pathways, the 5A2 microRNA mimic essentially starves the tumor of its preferred fuel sources while leaving healthy cells, which depend less heavily on these pathways, relatively unharmed.

Beyond cancer cells themselves, the metabolic environment of the tumor also shapes the immune response. Jin and colleagues reviewed the role of lactic acid, a byproduct of aerobic glycolysis, in regulating tumor-associated macrophages. These immune cells exist along a spectrum from pro-inflammatory M1 macrophages, which attack tumors, to anti-inflammatory M2 macrophages, which support tumor growth and suppress immune responses. Lactic acid has been shown to influence this M1-M2 balance, effectively tipping the tumor microenvironment toward a state that favors cancer progression. The authors argue that targeting lactate metabolism could reprogram these macrophages for enhanced anti-cancer immunity, particularly in solid tumors where immune suppression is strongest.

This metabolic crosstalk between tumor cells and immune cells represents a rapidly growing area of cancer research. Solid tumors create a hostile, nutrient-depleted, lactic acid-rich microenvironment that exhausts cytotoxic T cells and polarizes macrophages toward tumor-supportive states. By intervening in lactate signaling, researchers hope to convert immunologically cold tumors, which respond poorly to immunotherapy, into hot tumors that mount robust anti-cancer immune responses. This could improve the effectiveness of existing checkpoint inhibitors and open new avenues for combination treatments.

Adding another layer of complexity, Zhu and colleagues reviewed the role of mitochondrial ribosomal proteins in cancer. These proteins are essential for translating the thirteen proteins encoded by mitochondrial DNA, and changes in their expression have been linked to significant remodeling of the tumor microenvironment. Specific examples include MRPL13 in breast cancer, MRPL12, MRPL13, MRPL15 and MRPL42 in lung cancer, MRPL43 in colorectal cancer, MRPL9 and MRPL14 in head and neck cancer, and MRPL49 and CRIF1 in acute myeloid leukemia. These alterations drive oxidative stress, reactive oxygen species production, metabolic reprogramming and mitophagy, all of which contribute to cancer cell proliferation and metastasis.

What makes mitochondrial ribosomal proteins particularly exciting is their dual role as both therapeutic targets and prognostic biomarkers. Because their expression patterns differ across cancer types and correlate with disease progression, they could be used to stratify patients during chemotherapy treatment and to assess treatment impact in clinical trials. This aligns with the broader movement toward precision oncology, where molecular profiling of individual tumors guides therapeutic decisions tailored to each patient’s specific cancer biology.

Together, these studies illustrate that cancer’s metabolic rewiring is not a single pathway but an interconnected web spanning microRNA regulation, mitochondrial function, immune cell metabolism and nutrient utilization. While translating these findings into clinically approved treatments will require years of further research, the convergence of microRNA therapeutics, metabolic enzyme inhibitors and immune-modulating agents offers a promising multi-pronged strategy. As researchers continue to decode the metabolic language of tumors, the dream of targeting cancer’s engine room, rather than just its symptoms, moves steadily closer to reality.

Subject of Research: Cancer metabolic reprogramming as a therapeutic target

Article Title: Editorial: Targeting cancer metabolic reprogramming for cancer therapy

Article References: Geldenhuys, W. J., Ji, H. M., & Le, H. V. (2026). Editorial: Targeting cancer metabolic reprogramming for cancer therapy. Frontiers in Drug Discovery, 6, Article 1916506. https://doi.org/10.3389/fddsv.2026.1916506

Image Credits: AI Generated

DOI: 10.3389/fddsv.2026.1916506

Keywords: cancer, metabolism, microRNA, lactate, mitochondria, tumor microenvironment, drug discovery, Editorial, Targeting, metabolic, reprogramming, therapy